Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714336 · ClinicalTrials.gov registry record · Phase 4
Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 138
- Enrollment target
NCT01714336: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT01714336 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 138 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01714336, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 138 participants
- Enrollment target
Study Summary
Does tranexamic acid improve the perioperative care of those patients treated surgically for hip fracture by decreasing the proportion of patients requiring transfusion and decreasing total perioperative bleeding.
Interventions
- DRUG placebo
- DRUG tranexamic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2012-09 |
| Est. Completion | 2015-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01714336
The ClinicalTrials.gov registry entry for NCT01714336 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01714336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01714336 about?
NCT01714336 is a clinical study titled "Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?". Does tranexamic acid improve the perioperative care of those patients treated surgically for hip fracture by decreasing the proportion of patients requiring transfusion and decreasing total perioperative bleeding.
What is the current status of trial NCT01714336?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 138 participants. The study started on 2012-09. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01714336?
The interventions under investigation include: placebo (DRUG), tranexamic acid (DRUG).
Who is sponsoring clinical trial NCT01714336?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.